MC
PVCT

Marcus Capital’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Marcus Capital’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-15,000
Closed -$6K – 54
2015
Q4 		$6K Buy
+15,000
New +$7.11K 0.01% 49

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Marcus Capital's PVCT Position: Q1 2016 in Review

Marcus Capital sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q1 2016, closing a stake of 15,000 shares — an estimated $6K sold.

Marcus Capital first reported a position in PVCT in Q4 2015 and held it in 1 quarter. The position peaked at $6K in Q4 2015. 44 funds tracked by Wall St. Rank hold PVCT as of Q1 2016.

  • Marcus Capital reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q1 2016 after selling out during the quarter.
  • Marcus Capital sold 15,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q1 2016, an estimated $6K.
  • Marcus Capital first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2015 and held it in 1 quarter.
  • Marcus Capital's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $6K in Q4 2015.
  • 44 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2016.

Based on Marcus Capital's 13F filing for Q1 2016, filed 10 May 2016.